STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today
that it will host a conference call to discuss its fiscal 2020
third quarter financial results at 10:00 a.m. Eastern Time on
Tuesday, February 11, 2020. The conference call can be heard
live over the Internet at www.steris-ir.com or via phone by dialing
1-833-535-2199 in the United States or 1-412-902-6776
internationally, then asking to join the conference call for STERIS
plc.
A press release detailing third quarter financial results will
be issued after the U.S. market closes on Monday, February 10,
2020.
For those unable to listen to the conference call live, a replay
will be available beginning at 12:00 p.m. Eastern Time on February
11, 2020, either over the Internet at www.steris-ir.com or via
phone. To access the replay of the call, please use the
access code 10138127 and dial 1-877-344-7529 in the United States
or 1-412-317-0088 internationally.
About STERIS
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND
SAFER WORLD by providing innovative healthcare and life science
product and service solutions around the globe. For more
information, visit www.steris.com.
Investor Contact:
Julie Winter, Senior Director, Investor Relations and Corporate
Communications
Julie_Winter@steris.com
+1.440.392.7245
Media Contact:
Stephen Norton, Senior Director, Corporate Communications
Stephen_Norton@steris.com
+1.440.392.7482
Forward-Looking StatementsThis release and the
referenced conference call may contain statements concerning
certain trends, expectations, forecasts, estimates, or other
forward-looking information affecting or relating
to STERIS or its industry, products or activities that
are intended to qualify for the protections afforded
“forward-looking statements” under the Private Securities
Litigation Reform Act of 1995 and other laws and regulations.
Forward-looking statements speak only as to the date the statement
is made and may be identified by the use of forward-looking terms
such as “may,” “will,” “expects,” “believes,” “anticipates,”
“plans,” “estimates,” “projects,” “targets,” “forecasts,”
“outlook,” “impact,” “potential,” “confidence,” “improve,”
“optimistic,” “deliver,” “orders,” “backlog,” “comfortable,”
“trend”, and “seeks,” or the negative of such terms or other
variations on such terms or comparable terminology. Many important
factors could cause actual results to differ materially from those
in the forward-looking statements including, without limitation,
disruption of production or supplies, changes in market conditions,
political events, pending or future claims or litigation,
competitive factors, technology advances, actions of regulatory
agencies, and changes in laws, government regulations, labeling or
product approvals or the application or interpretation thereof.
Other risk factors are described in STERIS’s other securities
filings, including Item 1A of our Annual Report on Form 10-K
for the year ended March 31, 2019. Many of these important factors
are outside of STERIS’s control. No assurances can be provided as
to any result or the timing of any outcome regarding matters
described in STERIS’s securities filings or otherwise with respect
to any regulatory action, administrative proceedings, government
investigations, litigation, warning letters, cost reductions,
business strategies, earnings or revenue trends or future financial
results. References to products are summaries only and should not
be considered the specific terms of the product clearance or
literature. Unless legally required, STERIS does not
undertake to update or revise any forward-looking statements even
if events make clear that any projected results, express or
implied, will not be realized. Other potential risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements include, without
limitation, (a) STERIS's ability to achieve the expected benefits
regarding the accounting and tax treatments of the redomiciliation
to Ireland (“Redomiciliation”), (b) operating costs, Customer loss
and business disruption (including, without limitation,
difficulties in maintaining relationships with employees,
Customers, clients or suppliers) being greater than expected
following the Redomiciliation, (c) STERIS’s ability to meet
expectations regarding the accounting and tax treatment of the Tax
Cuts and Jobs Act (“TCJA”) or the possibility that anticipated
benefits resulting from the TCJA will be less than estimated,
(d) changes in tax laws or interpretations that could increase
our consolidated tax liabilities, including changes in tax laws
that would result in STERIS being treated as a domestic corporation
for United States federal tax purposes, (e) the potential for
increased pressure on pricing or costs that leads to erosion of
profit margins, (f) the possibility that market demand will
not develop for new technologies, products or applications or
services, or business initiatives will take longer, cost more or
produce lower benefits than anticipated, (g) the possibility
that application of or compliance with laws, court rulings,
certifications, regulations, regulatory actions, including without
limitation any of the same relating to FDA, EPA or other regulatory
authorities, government investigations, the outcome of any pending
or threatened FDA, EPA or other regulatory warning notices,
actions, requests, inspections or submissions, or other
requirements or standards may delay, limit or prevent new product
or service introductions, affect the production, supply and/or
marketing of existing products or services or otherwise affect
STERIS’s performance, results, prospects or value, (h) the
potential of international unrest, economic downturn or effects of
currencies, tax assessments, tariffs and/or other trade barriers,
adjustments or anticipated rates, raw material costs or
availability, benefit or retirement plan costs, or other regulatory
compliance costs, (i) the possibility of reduced demand, or
reductions in the rate of growth in demand, for STERIS’s products
and services, (j) the possibility of delays in receipt of
orders, order cancellations, or delays in the manufacture or
shipment of ordered products or in the provision of services,
(k) the possibility that anticipated growth, cost savings, new
product acceptance, performance or approvals, or other results may
not be achieved, or that transition, labor, competition, timing,
execution, regulatory, governmental, or other issues or risks
associated with STERIS’s businesses, industry or initiatives
including, without limitation, those matters described in our
Annual Report on Form 10-K for the year ended March 31, 2019, and
other securities filings, may adversely impact STERIS’s
performance, results, prospects or value, (l) the impact on
STERIS and its operations, or tax liabilities, of Brexit or the
exit of other member countries from the EU, and the Company’s
ability to respond to such impacts, (m) the impact on STERIS
and its operations of any legislation, regulations or orders,
including but not limited to any new trade or tax legislation,
regulations or orders, that may be implemented by the U.S.
administration or Congress, or of any responses thereto,
(n) the possibility that anticipated financial results or
benefits of recent acquisitions, or of STERIS’s restructuring
efforts, or of recent divestitures, or of restructuring plans
will not be realized or will be other than anticipated, and
(o) the effects of contractions in credit availability, as
well as the ability of STERIS’s Customers and suppliers to
adequately access the credit markets when needed.
STERIS (NYSE:STE)
Historical Stock Chart
From Aug 2024 to Sep 2024
STERIS (NYSE:STE)
Historical Stock Chart
From Sep 2023 to Sep 2024